In a report released today, Jason Wittes from Roth MKM maintained a Buy rating on Allurion Technologies (ALUR – Research Report), with a price ...

NATICK, Mass., February 19, 2025--(BUSINESS WIRE)--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity ...

Roth MKM lowered the firm’s price target on Allurion Technologies (ALUR) to $16 from $50 and keeps a Buy rating on the shares. The firm is ...

Research analysts at Roth Capital dropped their Q1 2025 EPS estimates for Allurion Technologies in a research note issued to investors on Wednesday, March 5th. Roth Capital analyst J. Wittes now ...

Allurion Technologies, Inc. develops treatments for obesity. The Allurion Program is a weight loss platform that combines the Allurion Gastric Balloon, a swallowable, procedure-less gastric ...

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will be partici ...

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced ...

Company considering sites in France for clinical trial on combination therapy of Allurion Balloon and GLP-1s to prevent muscle loss NATICK, Mass., February 13, 2025--(BUSINESS WIRE)--Allurion ...

NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a ...

ANSM, the French regulatory authority, clears Allurion to resume sales of the Allurion Balloon Company considering sites in France for clinical trial on combination therapy of Allurion Balloon and ...

Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline Allurion Technologies, Inc. (“Allurion” or the ...